R emember "six sigma?" In the 2000-2002 period, it was health care' s Next Big Idea, preoccupying its restless technocracy as the Health Insurance Portability and Accountability Act (HIPAA)-generated anxiety was waning and "consumer-driven health care" had yet to reach its current frenzy. Six sigma was and still is an important industrial engineering methodology developed by General Electric over several decades of practice and experimentation. As year-2000 (Y2K) and HIPAA conversions came and went, with great effort but none of the devastations predicted by the technocrats, six sigma filled an important void for the health care consulting industry in its eternal quest to generate billable hours.
care in general. Those who would use EBM to rein in the ever-expanding use of newer and better drugs-and thus reduce the costs associated with their use-are not interested in empirical reality, appropriateness, or any of the other ideals underlying the true EBM movement; they are desperate for a way to justify rationing but do not have the political courage to use the R-word.
Even the most casual review of EBM' s methods, in conjunction with an honest review of the literature of drug utilization across the U.S. population, reveals that EBM, as it is applied to pharmaceutical use, is a high-minded-sounding smokescreen for rationing care without saying as much. If EBM' s methods were applied to actual utilization patterns, EBM would expand rather than restrict the use of drugs, both across and within therapeutic classes. Nonetheless, the make-work exercise that is pharmaceutical EBM has come to dominate the policy-making activities of state Medicaid agencies and PBMs that seek ever newer and more intellectually defensible ways to restrict patients' access to care.
This article, as a direct confrontation with these agencies' alleged realpolitik, is intended to provide a badly needed reality check. Stripped of its current political packaging, what is EBM? When and why did it emerge? How does it really work? And what would drug utilization patterns across the United States look like if we applied EBM methods to a population that we know, according to actual EBM analyses conducted for nonpolitical reasons, is actually undermedicated?
II Evidence-Based Medicine 101
Before analyzing the soundness of applying EBM methods to pharmaceutical use, it is important to review the origins and conclusions of those methods. In its original incarnation, EBM involved the use of longitudinal empirical outcomes analyses to measure, in retrospect, the usefulness of diagnostic and surgical procedures. It is important for society to measure the outcomes associated with such procedures specifically because they do not undergo the same clinical testing, prior to their introduction into mainstream medical care, that drugs undergo prior to their approval by the U.S. Food and Drug Administration (FDA).
One needs to look no further than at the continuing struggle, after nearly 15 years of study, over whether or not Pap smears and mammograms actually reduce, respectively, long-term cervical and breast cancer mortality rates. The answers, according to EBM studies still in progress, vary greatly by age group (e.g., 40+ years versus 50+ years), periodicity (e.g., annual versus biannual), and myriad other risk factors for the disease. Judging by the literature, it seems that no two researchers can agree on any conclusion, at least not over time. This lack of agreement about the usefulness of clinical interventions, endemic to all of medicine, provides the crucial entry point for EBM' s newest champions, who argue that any intervention is guilty of uselessness until proven innocent One of the core assumptions of those who would apply EBM to drug use is that drug utilization patterns, when finally studied, would surely mirror the sloppy, uneven, and occasionally bizarre utilization patterns of diagnostic and surgical procedures uncovered by the EBM movement. EBM methods would show physicians how and how often their knee-jerk prescribing habits were inappropriate, the same way those methods have shown surgeons how and how often their propensity to operate has been inappropriate.
The goal of all EBM has been to add rationality to the clinical decision making of a medical community that, despite all its training and technology, engages in what often looks like folk art. Objective measures of medical practice, in a political vacuum, frequently reflect this notion. Such a vacuum does not account for things like defensive medicine, which is practiced to avoid frivolous medical malpractice lawsuits and thus compels the overuse of diagnostic testing, nor does it account for the dysfunctional economics of fee-for-service medicine, which compels the overuse of surgical procedures. This has led to the conclusion of EBM advocates that physician prescribing must be subject to the same tendency toward overuse.
But some of the tools of actual EBM, when applied to prescribing, do not confirm this presumption. In multiple research studies, Robert Dubois and colleagues have shown that we do not have variations in drug use approaching anything like what we have found in surgery. 3, 4 In one study of the medication of multiple disease states across California, the researchers found variations between highest and lowest rates of drug use of 1.3 to 1.4 times in the rates of diagnostic and surgical procedures documented by Wennberg and others.
The reliability of these numbers is confirmed by other researchers with an obvious commercial desire to find drug use variation. Motheral and colleagues from Express Scripts, a large, national pharmacy benefits manager that would be able to use variations as a rationale for marketing its services, found variations in medication use across regions that ranged from 1.7 to 1.9 for most medication classes. 5 This is why a few years from now the EBM movement, as misapplied to drug use, will have passed through health care with the permanence and profundity of six sigma reengineering. It is an intellectually bankrupt idea that will implode for the same reasons it has emerged-the current misapplication of EBM reflects an obsessive determination to manage money, not outcomes, not evidence, and certainly not disease. As has been demonstrated during numerous other attempts to reduce health spending by limiting access to expensive drugs, which actually are our best tool for managing overall health care costs, the use of EBM is certain to backfire.
The flow of almost all medical research-basic and applied, prospective and retrospective, privately and publicly fundedmoves us in one direction: more medicine is better. That should be obvious to anyone who has actually read a medical journal or any newspaper account over the last decade about breakthroughs in biomedical science, the rise of protein engineering, continual improvements in diagnostic technologies, and the decoding of the human genome. All of these scientific moving parts go toward building an ever more vivid understanding of the human machine and, thereby, ever greater opportunities for manipulating and preserving that machine with biochemistry. EBM, while ably pointing out that too many patients receive diagnostic and surgical procedures they did not need, will prove only what we already know from numerous research endeavors-too few patients receive drug care, not too many.
